TMS featured on the Dr. Oz Show

March 14, 2012 at 4:00 PM on Channel 7 (ABC), transcranial magnetic stimulation therapy used to treat resistant depression will be featured on the Dr. Oz Show. The show will feature a TMS physician and a patient, who has benefited from this effective non-pharmacological approach to treatment resistant depression. The TMS Center of Colorado is the first center in Colorado to use the Neurostar TMS therapy system in treating depression.

TMS is a non-invasive, non-systemic outpatient therapy for the treatment of major depressive disorders. The Neurostar Therapy System is FDA cleared for the treatment of depression in patients who have not received significant benefit from medication or who are not able to tolerate medications used to treat depression. For additional information about Neurostar TMS Therapy in Colorado contact our office at 303-884-3867.

To see NeuroStar featured on the Dr. Oz Show, follow the links below:
Dr. Oz TMS Part 1

Dr. Oz TMS Part 2

Tags: , , , ,

New Trial Data Confirm Clinical Effectiveness With NeuroStar TMS Therapy

Neuronetics sponsored an observational study of patients in the “real world” which confirms the clinical effectiveness and adherence rates of patients with Major Depressive Disorder (MDD) treated with the NeuroStar TMS Therapy system. This data continues to support the premise that patients with MDD who do not find relief with medication or who are unable to tolerate the medicines side effects have an effective, proven non-invasive and non-systemic  alternative.

“These data add to the impressive body of evidence that support the positive impact that TMS Therapy may have on patients living with major depression,” said Karl Lanocha, M.D., Medical Director of The TMS Center of New England, regarding the Neuronetics study.

The results of this study was released at the American Psychiatric Association meeting on May 15, 2011 in Hawaii.

The TMS Center of Colorado, LLC has been providing TMS therapy in Denver, Colorado since 2009. We serve the entire Rocky Mountain region including the front range communities; Colorado Springs, Boulder, Loveland, Fort Collins,  Longmont, Greeley, Denver as well as mountain communities such as Aspen, Vail and Steamboat Springs. We have also had patients from Wyoming, Montana and Missouri.

In addition to treating MDD, we are interested in the use of TMS for such off-label conditions as chronic pain, tinnitus, auditory hallucinations and Parkisons disease.

Tags: , , , , , , , ,

NeuroStar Magnetic Therapy helps a man after years of medication, shock therapy.

Transcranial Magnetic Stimulation (TMS or rTMS) can help many patients who have suffered for years with major depression. Many patients cannot tolerate the side effects of  medication or ECT. TMS has been proven in studies to be a safe and effective treatment for patients suffering from depression.

NeuroStar TMS (transcranial magnetic stimulation) Therapy is FDA-cleared for patients suffering from depression who have not achieved satisfactory improvement from undergoing prior prescribed rounds of antidepressant medications

TMS treatment has been FDA-cleared since 2008. The TMS Center of Colorado, LLC was the first NeuroStar provider of this therapy in Colorado. TMS Center of Colorado began accepting patients in late 2009.

Tags: , , ,

TMS Center of Colorado Makes KCNC News in Denver

Major Depressive Disorder (MDD) affects up to 50 million people in the USA. The affects of the disease on the person with MDD, their family and co-workers/employers can be devastating.  Time away from family and activities, lost work days and productivity, and side affects of  conventional treatment are some of the costs associated with MDD.  There is a relatively new treatment for MDD which was described in a television news segment which aired on March 22, 2011 on KCNC, Channel 4 in Denver.

This treatment is Transcranial Magnetic Stimulation TMS or rTMS).  NeuroStar TMS therapy is a FDA cleared treatment for major depressive disorder. TMS has also been used clinically in off label treatment and in clinical research to treat a wide variety of other neuorlogical and neuro-psychiatric conditions, including: chronic pain, post traumatic stress disorder (PTSD), phantom limb pain, depression associated with Parkinson’s Disease, post partum depression, tinnitus, auditory halucinations, and other conditions.

The NeuroStar TMS therapy system has been available in Colorado since November 2009 through the TMS Center of Colorado, LLC, located in Denver. This center was the first in Colorado (and the Rocky Mountain Region) to treat patients using this state of the art technology. There is hope for those suffering from MDD and other conditions.

Watch KCNC Coverage

Tags: , , , , , , , , , , , , ,

MD News – UAB’s New Magnetic Therapy for Depression Succeeds Where Drugs Fail

When medication fails a new, FDA cleared device may help: repetitive Transcranial Magnetic Stimulation is non-invasive, and non-systemic method of treating major depressive disorder.  MD News – UAB’s New Magnetic Therapy for Depression Succeeds Where Drugs Fail.

Tags: , , , , , ,

Magnetic Therapy May Prevent Depression Relapse

A recent study suggests that Transcranial Magmentic Stimulation may provide long lasting benefits to people who have not responded well to antidepressants.

Researchers from several international medical centers (including Rush University Medical Center, Stanford University Medical Center and the Mayo Clinic) selected 301 people with major depression that had proven resistant to antidepressant therapy. While 155 of the participants received a six-week treatment of TMS, 146 received a sham procedure.

A total of 142 people from either group whose depression abated after the six-week period went on to the second phase of the study, a three-week transition during which they were tapered off TMS treatment while starting on an antidepressant for maintenance therapy. During the six months that followed this phase, participants could receive additional TMS treatment if they showed signs of relapse.

Only 10% of the people who had originally responded well to TMS experienced a relapse in the six-month follow-up. What’s more, 84% of the people who received additional TMS treatment achieved symptom improvement and mood stability during the follow-up period demonstrating that TMS is a “meaningful rescue intervention.” The most common side effects of TMS reported in the study included insomnia, headache, anxietyand other effects.

TMS provides a relatively safe effective treatment for depression.

Tags: , , , , , , , ,

Brain differences in women with PostPartum Depression

 

Latest Depression News – Brain differences in women with PPD THURSDAY, Sept. 16, 2010 (HealthDay News) — Women with postpartum depression have differences in brain functioning that may interfere not only with how they process their own emotions, but also with their ability to be responsive to the emotions of their infants, new research suggests.

In a small study that involved MRI brain scans, researchers at the University of Pittsburgh Medical Center revealed that women with postpartum depression have reduced activity in parts of the brain that control emotional responses and recognize emotional cues in others.

“Our study provides a brain basis for what has been described in clinical settings and behavioral studies, which is that women with postpartum depression may have reduced activity in regions of the brain that process emotions and that are involved in being attuned to others’ emotions,” said study author Dr. Eydie L. Moses-Kolko, an assistant professor of psychiatry at the University of Pittsburgh School of Medicine. These brain abnormalities may help explain why mothers with postpartum depression often have problems bonding with their infants, she noted.

Postpartum depression, which affects an estimated 15 percent of new moms, is different than the typical “baby blues” that often occur after delivery, when a new mother may burst into tears at the drop of a hat, experts said.

While the baby blues usually go away within two weeks of giving birth, postpartum depression can continue for months and often causes such strong feelings of sadness, anxiety or despair that a woman has trouble coping with her daily tasks. Previous research has shown that maternal depression can negatively affect an infant’s mental and physical development.

Moses-Kolko and her colleagues studied 14 depressed and 16 healthy mothers, all of whom delivered a healthy term infant in the preceding 12 weeks, were medication-free and had previously given birth to another child. The mothers were shown images of angry and scared faces, and the researchers examined their neural reactions to the pictures with the use of MRI scans. The mothers also filled out questionnaires that assessed their attachment quality, hostility and pleasure in interaction with their infants.

The researchers found that negative emotional faces activated the left dorsomedial prefrontal cortex, which is a social cognition region of the brain, significantly less in depressed mothers than in healthy mothers. Deficits in this region, they said, might represent diminished awareness of the emotions of others and less empathy for them. Another key finding was that when the women saw negative images, communication between the left dorsomedial prefrontal cortex and the left amygdala was present in healthy moms but not in the depressed ones, suggesting that this might be an important neural circuit that regulates emotional response to unpleasant sounds, such as a baby’s cry.

The study, which was partly funded by the U.S. National Institute of Mental Health and the National Alliance for Research on Schizophrenia and Depression, was published Sept. 15 in the online advance edition of the

Moses-Kolko said more research is needed “to determine what brain patterns are predictive of response to an array of treatments including psychotherapy, medications or hormones.”

“This is a very interesting study, but it’s really just the beginning,” said Michael W. O’Hara, a professor of psychology at the University of Iowa in Iowa City, who specializes in perinatal depression. “More studies need to be done in a much larger sample of women, to see if the results can be replicated.”

O’Hara added: “It’s my belief that postpartum depression is a heterogeneous disorder that includes depression that is coincidental with childbirth, and depression that is inextricably related to it.” Future MRI studies need to differentiate between these two groups of women, he said, because “if we mix these two samples together, it may obscure the true findings.”

 

American Journal of Psychiatry. By Madonna Behen -

HealthDay Reporter Copyright © 2010 HealthDay. All rights reserved

 

Tags: , , , ,

World Economic Forum Announces 2011 Technology Pioneer

NeuroStar TMS (Transcranial Magnetic Stimulation) Therapy® system, has been selected by the World Economic Forum as a 2011 Technology Pioneer. Through a rigorous screening process, the World Economic Forum’s Technology Pioneers program identifies companies from around the world that develop and apply the most innovative and transformational technologies that have the promise of making a critical impact on the future of business and society. Many of the companies chosen are in a start-up phase or in their first rounds of financing. Companies selected as Technology Pioneers must demonstrate visionary leadership, show the potential for being a long-standing market leader, and have proven technology.  Neuronetics’ NeuroStar TMS Therapy system is the first and only non-systemic and non-invasive TMS device cleared by the U.S. Food and Drug Administration for the treatment of Major Depressive Disorder.

The TMS Center of Colorado is pleased to offer this state of the art treatement. TMS Center of Colorado the first center in the Colorado region to offer Neurostar TMS therapy for treatment of depression.

FDA Cleared treatment for Depression Available in Colorado

CONTACT: Mandie
Phone: 303-884-3867
E-mail: info@tmscenterofcolorado.com
Website: www.tmscenterofcolorado.com

First and Only Non-systemic and Non-Invasive Treatment for Depression
Now Available in Colorado

NeuroStar TMS Therapy® Offers New Hope to People Living with Depression

DENVER, CO (OCTOBER, 2009) –Transcranial Magnetic Stimulation (TMS) Therapy , a revolutionary new treatment for depression and a range of other neuropsychiatric disorders, is now available at The TMS Center of Colorado, the first private clinic to offer this exciting new treatment. The NeuroStar TMS Therapy® system is the first and only device of its kind to be cleared for the treatment of depression by the U.S. Food and Drug Administration (October 2008). The device is clinically proven for the treatment of major depression in adults who have failed to achieve satisfactory improvement from prior antidepressant medication.

“We are excited to be providing TMS Therapy and to be a part of this major step forward in psychiatry,” said Ted Wirecki MD, Medical Director and CEO. “Despite advances in treating depression, more than 30 percent of patients with this debilitating disease do not benefit from and/or are intolerant of antidepressant medications. Now, we have the option of offering patients the first and only non-systemic and non-invasive treatment for depression.”

TMS Therapy is a non-systemic (does not circulate in the bloodstream throughout the body) and non-invasive (does not involve surgery) form of neuromodulation that delivers highly-focused MRI-strength magnetic pulses to stimulate nerve cells in an area of the brain that is linked to depression. NeuroStar TMS Therapy is a 40-minute outpatient procedure that is prescribed by a psychiatrist, does not require anesthesia or sedation, and patients remain awake and alert.

NeuroStar TMS Therapy was demonstrated to be effective and safe in the treatment of depression in clinical trials. In an open-label clinical trial, which is most like real-world clinical practice, patients treated with NeuroStar TMS experienced a response rate (substantial improvement in symptoms) of 54% and 33% experienced remission (complete resolution of symptoms). Over 10,000 treatments were safely performed with no systemic side effects such as weight gain, sexual dysfunction, nausea, dry mouth, and sedation. The most common adverse event related to treatment was scalp pain or discomfort at the treatment area during active treatments, which was transient and mild to moderate in severity. The incidence of this side effect declined markedly after the first week of treatment.

“Studies demonstrated that treatment with NeuroStar TMS Therapy is safe and effective in patients who did not respond to prior antidepressant therapy,” said Dr. Wirecki. “Approximately 1 in 2 patients experienced a significant improvement in symptoms without side effects that are common with antidepressant medications.”

For more information about TMS at The TMS Center of Colorado, please contact Mandie Wolf at 303-884-3867 or mandie.wolf@tmscenterofcolorado.com.

About Depression
Depression affects at least 14 million American adults each year. Researchers estimate that by the year 2020, depression will be the second leading cause of disability worldwide. Each year, over 30,000 people in the U.S. commit suicide. 60 percent of these individuals suffer from depression. The economic burden of depression in 2000 was estimated at $83.1 billion in the U.S. Women are almost twice as likely as men to suffer from depression. However, some experts feel that depression in men is under-reported. About two-thirds of those who experience an episode of depression will have at least one other episode in their lives.

Tags: , , ,

Independent study shows rTMS helpful in treating depression

Independent research indicates the value of repetitive transcranial magnetic stimulation in treating depression with few side effects. This was reported in the Digital Journal on May 5, 2010 by Joan Firstenberg.

A study funded by the National Institutes of Mental Health, without any industry support, shows that magnet therapy can relieve depression and does so with few side effects.

Dr. Matthew Rudorfer, associate director for treatment research at the National Institute of Mental Health (NIMH) says this means that depression patients now have a new treatment option.

What is TMS Therapy?

TMS Therapy involves the use of very short pulses of magnetic energy to stimulate nerve cells in the brain. First used in 1985, TMS Therapy has been used by researchers around the world to help understand the function of different parts of the brain. Neuronetics’ pivotal trial was not the first to investigate the potential antidepressant effects of TMS Therapy, but it was the first one to lead to FDA approval of a TMS device for treatment of outpatients with depression. Results from other trials have encouraged researchers to further investigate TMS Therapy as a treatment for major depression and many studies are still ongoing around the world. 

How TMS Therapy Works
The short pulses of magnetic energy produced by NeuroStar® TMS Therapy System are aimed by the treating clinician at the structures in the brain thought to control mood. The left prefrontal cortex is used to access these structures non-invasively from outside the brain with TMS Therapy. The unique nature of magnetic fields allows them to pass through the skull and into the cortex without being distorted in any way. This facilitates a very focal type of stimulation, minimizing stimulation of brain tissue not involved in mood.   Once inside the brain, the dynamic (rapidly changing) nature of the magnetic pulses induces electrical charges to flow. The amount of electricity created in the brain is very small, and cannot be felt by the patient. When in the correct orientation relative to brain cells (neurons), these very small electric charges can cause the neurons to fire or become active. (Figure 3) The objective of TMS Therapy is to stimulate (or activate) brain cells. Patients remain awake and alert during a TMS Therapy procedure.

 

 

 

 

Tags: , , , , ,